Post-market

View Life Sciences by content type:

Latest Life Sciences News

Featured Life Sciences content

Practice notes
Rome II—application and interpretationThis Practice Note is for use when determining applicable law in respect of events giving rise to damage, where...
Read More >
19th May
Q&As
Can a third party rely on ostensible/apparent authority where they know the person signing a document is an employee of a company not a director and...
Read More >
19th May
Practice notes
Brexit—exiting the EU under Article 50 [Archived]ARCHIVED: This Practice Note has been archived and is not maintained.This Practice Note contains...
Read More >
Produced in partnership with Adam Cygan of University of Leicester 19th May
Practice notes
Antibiotic drug Nitrofurantoin (AMCo, Morningside Healthcare, Morningside Pharmaceuticals and Alliance Healthcare) (50507)CASE HUB See further,...
Read More >
19th May
Q&As
Can the board of a co-operative and community benefit society (a registered society) delegate powers to any third party, and can the registered...
Read More >
19th May
Practice notes
Rome Convention—introduction and interpretation [Archived]ARCHIVED: This Practice Note has been archived and is not maintained.The UK is no longer...
Read More >
19th May
Precedents
Coronavirus (COVID-19): In addition to the below content on force majeure generally, see also: • Coronavirus (COVID-19)...
Read More >
19th May
Practice notes
Many companies and government bodies (such as HMRC) have been exposed to loss of confidential information and many other breaches of confidentiality...
Read More >
19th May
Practice notes
Introduction to retained EU lawThis Practice Note provides an introduction to retained EU law. It provides an overview of the key definitions and...
Read More >
Produced in partnership with Dr. Kieran Laird of Gowling WLG 19th May
Precedents
1 Counterparts—agreement 1.1 This agreement may be signed in any number of separate counterparts, each of which when...
Read More >
19th May
Practice notes
Model ADR clausesThis Practice Note considers model form alternative dispute resolution (ADR) clauses provided by a number of service providers,...
Read More >
19th May
Precedents
Option 1—contract signed on behalf of a company, where the authorised signatory is an individual Signed by [insert name of...
Read More >
19th May
Practice notes
Requirements of the company sealThis Practice Note provides practical guidance regarding the requirements of the company seal. Where a company has a...
Read More >
19th May
Practice notes
Brexit implementation period—enforcement [Archived]ARCHIVED: This Practice Note has been archived and is not maintained.This Practice Note considers...
Read More >
19th May
Practice notes
SubcontractingThis Practice Note examines the following legal and practical matters in relation to entering into a subcontract or when granting...
Read More >
19th May
Practice notes
ScopeThis Practice Note explains trade mark law on parallel trade. Parallel imports, or ‘grey market’ goods, are genuine goods that are placed on the...
Read More >
Produced in partnership with Taylor Wessing LLP 19th May

Most recent Post-market content

Practice notes
Anti-counterfeiting in the UKThis Practice Note summarises the main types of legal action that can be taken against the UK trade in counterfeit goods,...
Read More >
Produced in partnership with Taylor Wessing LLP 3rd Sep
Practice notes
Product liability in the life sciences sectorThe UK regulatory framework for product liability has mainly originated from EU law. Many principles and...
Read More >
17th Aug
Practice notes
Defective productsThis Practice Note summarises the law on defective products under the Consumer Protection Act 1987 (CPA 1987) and Council Directive...
Read More >
Produced in partnership with Alison Newstead of Shook, Hardy & Bacon International LLP, Simon Castley of Shook, Hardy & Bacon International LLP and Marisa Pearce of Shook, Hardy & Bacon International LLP 11th Aug
Precedents
Product recall clause1Product recall clause—pro-supplier1.1The Customer shall immediately notify the Supplier if it becomes aware of any complaint or...
Read More >
Produced in partnership with Emma Spence of DWF LLP and David Kidman of DWF LLP 11th Aug
Practice notes
Sale of counterfeit goods onlineIP COMPLETION DAY: The Brexit transition period ended at 11pm on 31 December 2020. At this time (referred to in UK law...
Read More >
9th Aug
Q&As
Is there any prohibition against the subcontracting of QPPV services?The Guideline on good pharmacovigilance practices (GVP) (PV Guidance) provides...
Read More >
31st Jul
Q&As
In summary, what is the current position regarding product liability in the life sciences sector?The following Practice Notes are useful when...
Read More >
31st Jul
Q&As
Are there any requirements to monitor medicines once they have been authorised and placed on the market?All medicinal products in the EU are subject...
Read More >
31st Jul
Practice notes
PharmacovigilancePharmacovigilance is the process of collecting and understanding information relating to the adverse effects of medicinal product...
Read More >
Produced in partnership with Eveline Van Keymeulen of Allen & Overy LLP and Jeanne Fabre of Allen & Overy LLP 31st Jul
Practice notes
Brexit—implications of the Withdrawal Agreement for the life sciences sector [Archived]ARCHIVED: This Practice Note has been archived and is not...
Read More >
31st Jul
Q&As
Does a marketing authorisation holder (MAH) of a medicinal product need to collect information on individual cases of ‘off-label’ use if there is no...
Read More >
31st Jul
Practice notes
Parallel importsScopeThis Practice Note explains trade mark law on parallel trade. Parallel imports, or ‘grey market’ goods, are genuine goods that...
Read More >
Produced in partnership with Taylor Wessing LLP 31st Jul
Practice notes
Pharmaceutical trade marks and parallel importsAt 11 pm on 31 December 2020 (IP completion day), the UK ceased to be subject to EU law. The UK’s...
Read More >
Produced in partnership with Oscar Benito of Gavi, the Vaccines Alliance 31st Jul
Practice notes
What does IP completion day mean for medicinal products?11 pm (GMT) on 31 December 2020 marked the end of the implementation period put in place to...
Read More >
31st Jul
Q&As
What are the obligations that a QPPV must perform?Article 104(3) of Directive 2001/83/EC (consolidated version 26.07.2019), the Pharmaceutical Code...
Read More >
31st Jul
Q&As
How does the General Data Protection Regulation affect the pharmacovigilance sector?Pharmacovigilance (PV) is the practice of monitoring the effects...
Read More >
Produced in partnership with Rishi Wadwha of International Association of Privacy Professionals 31st Jul
Practice notes
Falsified medicinesA worldwide problem, for developed and developing countries alike, is the trade of falsified medicinal products. The terms...
Read More >
Produced in partnership with Elisabethann Wright of Cooley LLP and Fabien Roy, Jane Summerfield, Alexander Wenzel, Hélène Boland, Hannah Kerr-Peterson, Jessica Koffel and Silvia Lopez Arnao of Hogan Lovells 31st Jul

Popular documents